Molecular mechanisms of tumor angiogenesis and tumor progression

Journal of Neuro-Oncology

Volumn 50, Issue 1-2, 2000, Pages 63-70

  Cavallaro, U ^a   Christofori, G ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Angiogenesis; Metastasis; Oncogenes; Tumor suppressor genes; Tumorigenesis

Indexed keywords

2 METHOXYESTRADIOL; ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOPOIETIN; ANGIOSTATIN; ANGIOTROPHIN; BASIC FIBROBLAST GROWTH FACTOR; BETA CYCLODEXTRIN; CX3C CHEMOKINE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROCORTISONE; INTERLEUKIN 8; PENICILLAMINE; PLATELET DERIVED GROWTH FACTOR BB; PLEIOTROPHIN; THALIDOMIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BINDING AFFINITY; CANCER INHIBITION; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; METASTASIS; MIGRATION INHIBITION; MOLECULAR BIOLOGY; MORPHOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; COLLAGEN; DISEASE PROGRESSION; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034471796     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006414621286     Document Type: Review

References (80)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. How tumors become angiogenic
4. Mechanisms of angiogenesis
5. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
6. Angiogenesis: A dynamic balance of stimulators and inhibitors
7. Signaling angiogenesis and lymphangiogenesis
8. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
9. The biology of vascular endothelial growth factor
10. The role of fibroblast growth factors in tumor progression and angiogenesis
11. Fibroblast growth factors in tumor progression and angiogenesis
12. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor
13. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization
14. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries. An autocrine mechanism contributing to angiogenesis
15. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells
16. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
17. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
18. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
19. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
20. Angiogenesis
21. Angiogenesis and tumor metastasis
22. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses
23. Inhibition of angiogenesis in vivo by interleukin 12
24. Grobeta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice
25. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
26. Integrins and cancer
27. The role of alphav integrins during angiogenesis
28. Clinical applications of angiogenic growth factors and their inhibitors
29. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
30. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
31. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
32. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth
33. The role of basement membranes in vascular development
34. Thrombospondin as an inhibitor of angiogenesis
35. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells
36. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
37. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
38. Angiostatin binds ATP synthase on the surface of human endothelial cells
39. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
40. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells
41. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
42. Multiple forms of angiostatin induce apoptosis in endothelial cells
43. Inhibitory effect of full-length human endostatin on in vitro angiogenesis
44. Endostatin induces endothelial cell apoptosis
45. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin
46. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls
47. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not complete for fibroblast growth factor-2 binding
48. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
49. Zinc-binding of endostatin is essential for its antiangiogenic activity
50. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis
51. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
52. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
53. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
54. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function
55. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src
56. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma
57. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells
58. Tumor induction of VEGF promoter activity in stromal cells
59. The implication of angiogenesis on tumor invasiveness
60. Novel forms of acidic fibroblast growth factor-1 are constitutively exported by β tumor cell lines independent from conventional secretion and apoptosis
61. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
62. Establishing a link between oncogenes and tumor angiogenesis
63. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
64. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF)
65. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
66. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice
67. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
68. Halting angiogenesis suppresses carcinoma cell invasion
69. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin
70. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma
71. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
72. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma
73. Angiostatin induces and sustains dormancy of human primary tumors in mice
74. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
75. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
76. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
77. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
78. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
79. A cancer therapy resistant to resistance
80. Endogenous angiogenesis inhibitors: Angiostatin, endostatin, and other proteolytic fragments